CytomX Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
CytomX Therapeutics, Inc. (CTMX) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $4.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-08-06
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2026-06-30 was $100.00K.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2026-03-31 was $4.40M, a 4.76% increase year-over-year.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2025-12-31 was $100.00K.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2025-09-30 was $100.00K, a 0.00% change year-over-year.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $4.40M, a 7.32% increase from fiscal 2024.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $4.10M.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2017 was $0.00.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2016 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.50M 10-Q · filed 2026-08-06 | $4.60M derived: sum of 3 quarters · filed 2026-08-06 | $4.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.40M 10-Q · filed 2026-05-07 | $4.50M derived: sum of 2 quarters · filed 2026-05-07 | $4.60M derived: sum of 3 quarters · filed 2026-05-07 | $4.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $200.00K derived: sum of 2 quarters · filed 2026-03-16 | $200.00K derived: sum of 3 quarters · filed 2026-03-16 | $4.40M 10-K · filed 2026-03-16 |
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $100.00K derived: sum of 2 quarters · filed 2025-11-06 | $4.30M 10-Q · filed 2025-11-06 | $4.30M derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.20M 10-Q · filed 2025-08-07 | $4.20M derived: sum of 3 quarters · filed 2025-08-07 | $4.30M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $4.20M 10-Q · filed 2025-05-12 | $4.20M derived: sum of 2 quarters · filed 2025-05-12 | $4.30M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $100.00K derived: sum of 2 quarters · filed 2025-03-06 | $4.10M 10-K · filed 2025-03-06 | |
| 2024-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.10M 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $4.00M 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $3.90M 10-Q · filed 2024-05-08 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $0.00 derived: sum of 3 quarters · filed 2018-03-07 | $0.00 10-K · filed 2018-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | $0.00 derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $0.00 10-Q · filed 2017-08-07 | $0.00 derived: sum of 3 quarters · filed 2017-08-07 | $0.00 derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | $0.00 derived: sum of 2 quarters · filed 2017-05-05 | $0.00 derived: sum of 3 quarters · filed 2017-05-05 | $0.00 derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $0.00 derived: sum of 2 quarters · filed 2017-03-02 | $0.00 derived: sum of 3 quarters · filed 2017-03-02 | $0.00 10-K · filed 2017-03-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $0.00 10-Q · filed 2016-08-03 | $0.00 derived: sum of 3 quarters · filed 2016-08-03 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-06 | $0.00 derived: sum of 2 quarters · filed 2016-05-06 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-07 | $0.00 10-K · filed 2016-03-07 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |